4:06 PM ET
8-K
Reverse Stock Split
Sunshine Biopharma Reverse Stock Split
Sunshine Biopharma's majority shareholder, CEO Dr. Steve N. Slilaty, has approved a written consent authorizing the board to effect a reverse stock split at a ratio of up to 1-for-20. The board retains discretion over the final ratio and the timing of the split, which will become effective 20 days after a definitive information statement is mailed to stockholders.